Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Van Gulick

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Behavioral and Brain Sciences|November 15, 2011
Drugs, mental instruments, and self-controlRobert Van Gulick
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidineChiara R Dart, Nabanita Mukherjee, Carol M Amato, et al.
Cancers|May 14, 2022
BRAF Modulates Lipid Use and AccumulationJacqueline A Turner, Emily L Paton, Robert Van Gulick, et al.
Nature Communications|June 3, 2023
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunityJacqueline A Turner, Malia A Fredrickson, Marc D'Antonio, et al.
Oncogene|September 27, 2018
BRAF fusions identified in melanomas have variable treatment responses and phenotypesJacqueline A Turner, Judson G T Bemis, Stacey M Bagby, et al.
Cancers|August 9, 2020
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced MelanomaNabanita Mukherjee, Carol M Amato, Jenette Skees, et al.
Cell Death & Disease|June 10, 2020
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsNabanita Mukherjee, Jenette Skees, Kaleb J Todd, et al.
Nature Communications|October 17, 2020
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversityFelicity Newell, James S Wilmott, Peter A Johansson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Behavioral and Brain Sciences|November 15, 2011
Drugs, mental instruments, and self-controlRobert Van Gulick
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidineChiara R Dart, Nabanita Mukherjee, Carol M Amato, et al.
Cancers|May 14, 2022
BRAF Modulates Lipid Use and AccumulationJacqueline A Turner, Emily L Paton, Robert Van Gulick, et al.
Nature Communications|June 3, 2023
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunityJacqueline A Turner, Malia A Fredrickson, Marc D'Antonio, et al.
Oncogene|September 27, 2018
BRAF fusions identified in melanomas have variable treatment responses and phenotypesJacqueline A Turner, Judson G T Bemis, Stacey M Bagby, et al.
Cancers|August 9, 2020
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced MelanomaNabanita Mukherjee, Carol M Amato, Jenette Skees, et al.
Cell Death & Disease|June 10, 2020
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsNabanita Mukherjee, Jenette Skees, Kaleb J Todd, et al.
Nature Communications|October 17, 2020
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversityFelicity Newell, James S Wilmott, Peter A Johansson, et al.
Pageof 1